-
Something wrong with this record ?
Therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis
V. Rehácek, M. Bláha, H. Jirousová, J. Cernohorská, P. Papousek
Language English Country Czech Republic
Document type Journal Article
Digital library NLK
Full text - Article
Issue
Volume
Source
Source
NLK
Directory of Open Access Journals
from 1997
Free Medical Journals
from 1997
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 2012-06-01
ROAD: Directory of Open Access Scholarly Resources
from 1997
- MeSH
- Adult MeSH
- Hematocrit MeSH
- Hemochromatosis blood genetics therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Erythrocyte Volume MeSH
- Aged MeSH
- Blood Component Removal * MeSH
- Transferrin analysis MeSH
- Erythrocyte Transfusion * MeSH
- Iron blood MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The current treatment of hereditary hemochromatosis (HH) consists of performing periodic whole blood phlebotomies. Erythrocytapheresis (EA) can remove up to three times more red blood cells per single procedure and could thus have a clinical benefit. A prospective study of 30 consecutive cases of HH were included in a periodic EA program. METHODS AND PATIENTS: EA were performed using a discontinuous flow cell separators. The protocol consisted of a bimonthly EA until normalization of the serum ferritin was reached. The aim was to reduce the total erythrocyte volume by 25-35%, eventually, to adjust the amount so that hematocrit would not drop below 0.25. RESULTS: 530 +/- 101 ml of erythrocytes were removed (median 517, range 116-761 ml). Iron depletion (ferritin < 20 microg/l) was achieved in all patients after a mean 6.9 +/- 7.6 months, median 5 months, range 1-36 months and a mean 14 EA sessions. The procedures were well tolerated and there were no severe side-effects. CONCLUSIONS: We conclude that HH patients treated with EA achieved iron depletion quickly under good conditions of tolerance. The efficacy, speed, tolerability, and more favorable schedule of an EA program facilitate treatment of HH.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13037648
- 003
- CZ-PrNML
- 005
- 20131129100512.0
- 007
- ta
- 008
- 131126s2012 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/18059694.2015.43 $2 doi
- 035 __
- $a (PubMed)23631289
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Řeháček, Vít $u Transfusion Department Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové $7 xx0103850
- 245 10
- $a Therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis / $c V. Rehácek, M. Bláha, H. Jirousová, J. Cernohorská, P. Papousek
- 520 9_
- $a BACKGROUND: The current treatment of hereditary hemochromatosis (HH) consists of performing periodic whole blood phlebotomies. Erythrocytapheresis (EA) can remove up to three times more red blood cells per single procedure and could thus have a clinical benefit. A prospective study of 30 consecutive cases of HH were included in a periodic EA program. METHODS AND PATIENTS: EA were performed using a discontinuous flow cell separators. The protocol consisted of a bimonthly EA until normalization of the serum ferritin was reached. The aim was to reduce the total erythrocyte volume by 25-35%, eventually, to adjust the amount so that hematocrit would not drop below 0.25. RESULTS: 530 +/- 101 ml of erythrocytes were removed (median 517, range 116-761 ml). Iron depletion (ferritin < 20 microg/l) was achieved in all patients after a mean 6.9 +/- 7.6 months, median 5 months, range 1-36 months and a mean 14 EA sessions. The procedures were well tolerated and there were no severe side-effects. CONCLUSIONS: We conclude that HH patients treated with EA achieved iron depletion quickly under good conditions of tolerance. The efficacy, speed, tolerability, and more favorable schedule of an EA program facilitate treatment of HH.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a separace krevních složek $7 D001781
- 650 12
- $a transfuze erytrocytů $7 D017707
- 650 _2
- $a objem erytrocytu $7 D004911
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hematokrit $7 D006400
- 650 _2
- $a hemochromatóza $x krev $x genetika $x terapie $7 D006432
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a železo $x krev $7 D007501
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a transferin $x analýza $7 D014168
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bláha, Milan, $u 4th Department of Medicine, Hematology, Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové $d 1938- $7 xx0034440
- 700 1#
- $a Jiroušová, Hana $u Transfusion Department Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové $7 xx0301946
- 700 1#
- $a Černohorská, Jitka $u Transfusion Department Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové $7 xx0231605
- 700 1_
- $a Papoušek, Petr $u Transfusion Department Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové $7 xx0108125
- 773 0_
- $w MED00010947 $t Acta medica (Hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové $x 1211-4286 $g Roč. 55, č. 4 (2012), s. 180-185
- 856 41
- $u https://actamedica.lfhk.cuni.cz/media/pdf/am_2012055040180.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 3077 $c 1072 $y a $z 0
- 990 __
- $a 20131126 $b ABA008
- 991 __
- $a 20131129100900 $b ABA008
- 999 __
- $a ok $b bmc $g 1002271 $s 836138
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 55 $c 4 $d 180-185 $i 1211-4286 $m Acta Medica $n Acta Med. (Hradec Král.) $x MED00010947
- LZP __
- $b NLK111 $a Pubmed-20131126